In a similar study by the Medicines and Healthcare Products Regulatory Agency in UK where the target population was cancer patients, using pharmacokinetic screening did not only proof useful in attaining important clinical information but also was seen to be a generally cost-effective approach to get such information pertaining to both pharmacokinetic and pharmacodynamic variability in treated patients (Ruiz-Garcia, Bermejo, Moss and Casabo, 2008). One other major contribution of population pk to drug development is the ability to base on outcomes with population pk studies to customize pharmacotherapy. In a study by Raymond and Brasseur (2005), it was found that there are several factors that make this outcome with customized pharmacology possible. In the first place, population pk requires that multiple samples from one person are not used. In effect, variability in drug concentrations is achieved for very specific patient populations (Bonate, 2005). This way, it is possible to assign differences in pharmacokinetics to specific patient characteristics and hence customization of pharmacotherapy. In the second instance, it is seen that when population pk is used, it is possible to emphasize on subgroups of populations. . Contribution of Population-Pharmacokinetics to Drug Development.
Baaske P, Wienken CJ, Reineck P, Duhr S and Braun D (2010). "Optical Thermophoresis quantifies Buffer dependence of Aptamer Binding". Angewandte Chemie International Edition, Vol. 49 No. 12, pp. 1–5.
Bartelink I.H., Rademaker C.M., Schobben A.F., et al. (2006). Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clinical Pharmacokinetics, Vol. 45 No. 11, pp. 1077–1097.
Bonate P.L. (2005). "Recommended reading in population pharmacokinetic pharmacodynamics". The AAPS Journal, Vol. 7 No. 2, pp. 363–73.
Ernest T.B., Elder D.P., Martini LG, et al. (2007). Developing paediatric medicines: identifying the needs and recognizing the challenges. Journal of Pharmacology and Pharmacotherapeutics, Vol. 59 No. 8:1043–1055.
Greenberg M. D. (2000). AIDS, experimental drug approval, and the FDA new drug screening process. Legislation and public policy, vol. 3 No. 2, pp. 295-303
Hsieh Y. and Korfmacher W.A. (2006). "Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening". Current Drug Metabolism Vol. 7 No. 5, pp. 479–89.
Jagdale S.C., Patil S.A., Kuchekar B.S. and Chabukswar (2011). Preparation and Characterization of Metformin Hydrochloride — Compritol 888 ATO Solid Dispersion. Journal of Young Pharmacists. Vol. 3 No. 3, pp. 197–204
Jager T., Albert C., Preuss T.G. and Ashauer R. (2011). "General unified threshold model of survival--a toxicokinetic-toxicodynamic framework for ecotoxicology". Environmental Science & Technology, Vol. 45 No. 7, pp. 2529–40.
Leeder J.S. (2004). Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discovery Today. Vol. 9 No. 13, pp. 567–573.
Raymond A. and Brasseur D. (2005). Development of medicines for children in Europe: ethical implications. Paediatric Respiratory Reviews, Vol. 6 No. 1, pp. 45–51.
Roosmarijn F. W. et al. (2011). The role of population PK–PD modelling in paediatric clinical research. European Journal of Clinical Pharmacology. 67, pp. 5-16.
Ruiz-Garcia A., Bermejo M., Moss A. and Casabo V.G. (2008). "Pharmacokinetics in drug discovery". Journal of Pharmaceutical Sciences, Vol. 97 No. 2, pp. 654–90.
Samara E. and Granneman R. (1997). Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective. Clinical Pharmacokinetics, Vol. 32 No. 4, pp. 294-312
Tucker G.T. (2012). "Research priorities in pharmacokinetics". British Journal of Clinical Pharmacology, Vol. 73 No. 6, pp. 924–6.
Please type your essay title, choose your document type, enter your email and we send you essay samples